Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR30.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR37.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR46.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR41.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR36.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR47.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR28.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR29.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR35.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR26.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR17.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR45.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR48.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR33.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR25.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR49.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR23.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR39.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR32.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR19.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR40.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR44.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR22.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR18.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR42.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR21.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR34.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR43.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR15.htm
EX-31.2 - EX-31.2 - ARIAD PHARMACEUTICALS INCd413091dex312.htm
EX-32.1 - EX-32.1 - ARIAD PHARMACEUTICALS INCd413091dex321.htm
EX-31.1 - EX-31.1 - ARIAD PHARMACEUTICALS INCd413091dex311.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR20.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR27.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR38.htm
10-Q - 10-Q - ARIAD PHARMACEUTICALS INCd413091d10q.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR24.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR31.htm
v2.4.0.6
Intangible and Other Assets, Net
9 Months Ended
Sep. 30, 2012
Intangible and Other Assets, Net
4. Intangible and Other Assets, Net

Intangible and other assets, net, were comprised of the following at September 30, 2012 and December 31, 2011:

 

In thousands    September 30,
2012
    December 31,
2011
 

Capitalized patent and license costs

   $ 5,992      $ 6,799   

Purchased technology

     —          5,901   
  

 

 

   

 

 

 
     5,992        12,700   

Less accumulated amortization

     (4,977     (6,957
  

 

 

   

 

 

 
     1,015        5,743   

Other assets

     1,933        42   
  

 

 

   

 

 

 
   $ 2,948      $ 5,785   
  

 

 

   

 

 

 

Amortization expense for intangible assets amounted to $4,000 and $728,000 for the three-month periods ended September 30, 2012 and 2011, respectively, and amounted to $213,000 and $1.3 million for the nine-month periods ended September 30, 2012 and 2011, respectively. The weighted average amortization period for intangible assets was 17.0 years in 2012 and 15.3 years in 2011.

In addition to amortization expense, during the nine-month period ended September 30, 2012, the Company recorded charges to operating expenses of $4.8 million to reflect impairment of the carrying value of intangible assets associated with ridaforolimus, the Company’s investigational oral mTOR inhibitor being developed by Merck & Co., Inc. (“Merck”) for oncology indications pursuant to a license with the Company, following the decision in June 2012 by the U.S. Food and Drug Administration (“FDA”) to not approve the New Drug Application (“NDA”) filed by Merck for the treatment of patients with soft tissue or bone sarcomas, stating that additional clinical trial(s) would need to be conducted to further assess safety and efficacy of ridaforolimus in this indication. The impairment of the carrying value of ridaforolimus intangible assets was based on management’s assessment of the uncertainty related to the timing and amount of future cash flows anticipated from these assets.